/APVO
APVO Stock - Aptevo Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$1.07+2.88%
+$0.03 (+2.88%) • Dec 19
47
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.63
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.18
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for APVO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.06 – $1.08
TARGET (TP)$1.23
STOP LOSS$0.98
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.42
52W High$109.80
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $3.11M | $12.29M | $4.31M |
| Gross Profit | $-352,000 | N/A | $3.11M | $12.29M | $-13,543,000 |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | -314.3% |
| Operating Income | $-24,602,000 | $-28,878,000 | $-28,641,000 | $-21,400,000 | $-27,494,000 |
| Net Income | $-24,130,000 | $-17,411,000 | $8.03M | $-28,457,000 | $-17,750,000 |
| Net Margin | N/A | N/A | 257.8% | -231.5% | -411.9% |
| EPS | $-1747.68 | $-46335.00 | $51243.00 | $-197647.00 | $-308112.00 |
Company Overview
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
APVOBeat Rate
61%
Last 18 quarters
Avg Surprise
-138.6%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$-2.23
Q4 2025
EPS Surprise History
Q1 24
+65.9%
$-6.16vs$-18.04
Q2 24
+29.4%
$-360.51vs$-510.87
Q3 24
+13.5%
$-60.51vs$-69.93
Q4 24
+15.8%
$-17.39vs$-20.65
Q1 25
-962.8%
$-82.37vs$-7.75
Q2 25
-4.3%
$-87.80vs$-84.20
Q3 25
-1766.7%
$-8.40vs$-0.45
Q4 25
-6.7%
$-2.23vs$-2.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 13, 2026 | $-0.45 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-2.09 | $-2.23 | -6.7% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.45 | $-8.40 | -1766.7% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-84.20 | $-87.80 | -4.3% | ✗ MISS |
Q1 2025 | Mar 4, 2025 | $-7.75 | $-82.37 | -962.8% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-20.65 | $-17.39 | +15.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-69.93 | $-60.51 | +13.5% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-510.87 | $-360.51 | +29.4% | ✓ BEAT |
Q1 2024 | Mar 5, 2024 | $-18.04 | $-6.16 | +65.9% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-1149.21 | $-798.06 | +30.6% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1787.65 | $-1963.23 | -9.8% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-1899.38 | $414.99 | +121.8% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-1.53 | $-0.95 | +37.9% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-2617.63 | $-2442.06 | +6.7% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-2122.84 | $-2968.78 | -39.8% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1835.54 | $-2537.83 | -38.3% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-1.29 | $-1.27 | +1.6% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-2362.26 | $-2314.37 | +2.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-3112.43 | $-2841.09 | +8.7% | ✓ BEAT |
Latest News
Aptevo Therapeutics Presents Preliminary Results From Ongoing Phase 1b/2 RAINIER Study Evaluating Mipletamig In Combination With AZA/VEN For Newly Diagnosed AML Patients, At ASH Annual Meeting
➖ NeutralBenzinga•Dec 9, 2025, 01:12 PM
Aptevo Highlights Nov. 8 Presentation Of APVO451 Data At Society for Immunotherapy of Cancer (SITC) Annual Meeting
📈 PositiveBenzinga•Nov 10, 2025, 01:13 PM
Aptevo Therapeutics Q3 EPS $(2.23) Misses $(2.09) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 01:37 PM
Aptevo Therapeutics shares are trading higher Steven Cohen reported a 9.1% passive stake in the company.
📈 PositiveBenzinga•Sep 18, 2025, 02:14 PM
Market-Moving News for September 18th
➖ NeutralBenzinga•Sep 18, 2025, 11:21 AM•Also: ,
Steven Cohen Reports 9.1% Passive Stake In Aptevo Therapeutics As Of September 16
📈 PositiveBenzinga•Sep 17, 2025, 09:37 PM
Aptevo Therapeutics shares are trading higher after the company reported a 100% remission rate in Cohort 3 of its RAINIER trial for AML with Mipletamig.
📈 PositiveBenzinga•Sep 16, 2025, 12:35 PM
Aptevo's Mipletamig Achieves 100% Remission With Favorable Safety In Phase 1b/2 AML Trial; Cohort 4 Now Open For Enrollment
📈 PositiveBenzinga•Sep 16, 2025, 12:33 PM
Aptevo Expands Anti-Cancer Pipeline With Patents For APVO452, APVO451; Acute Myeloid Leukemia Candidate Mipletamig Shows Strong Clinical Validation
📈 PositiveBenzinga•Sep 4, 2025, 12:50 PM
Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double
📈 PositiveSeeking Alpha•Jun 18, 2025, 03:29 PM
Frequently Asked Questions about APVO
What is APVO's current stock price?
Aptevo Therapeutics Inc. (APVO) is currently trading at $1.07 per share. The stock has moved +2.88% today.
What is the analyst price target for APVO?
No analyst price targets are currently available for this stock.
What sector is Aptevo Therapeutics Inc. in?
Aptevo Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is APVO's market cap?
Aptevo Therapeutics Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does APVO pay dividends?
No, Aptevo Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABP
Abpro Corporation
$5.06
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
CERO
CERo Therapeutics Holdings, Inc.
$0.10
Mkt Cap: $0.0B
EPIX
ESSA Pharma Inc.
$0.20
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$1.21
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
MTNB
Matinas BioPharma Holdings, Inc.
$0.73
Mkt Cap: $0.0B
RADX
Radiopharm Theranostics Limited
$5.19
Mkt Cap: $0.0B
Explore stocks similar to APVO for comparison